We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CBO: DRUG FIRMS COULD THWART PRICE CUTS UNDER IMPORTATION
CBO: DRUG FIRMS COULD THWART PRICE CUTS UNDER IMPORTATION
April 30, 2004
Drugmakers — especially brand companies — have several options for minimizing the effects of changes in Rx drug importation policy on U.S. pharmaceutical prices, including gaining FDA and foreign-government cooperation in limiting the trade practice, according to a report from the Congressional Budget Office (CBO).